{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:32:35Z","timestamp":1763105555523,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/s1470-2045(17)30695-2","type":"journal-article","created":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T08:45:23Z","timestamp":1507970723000},"page":"1437-1439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adjuvant zoledronic acid to treat breast cancer: not for all"],"prefix":"10.1016","volume":"18","author":[{"given":"Lu\u00eds","family":"Costa","sequence":"first","affiliation":[]},{"given":"Arlindo R","family":"Ferreira","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(17)30695-2_bib1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(17)30695-2_bib2","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(17)30695-2_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel","volume":"27","author":"Hadji","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(17)30695-2_bib4","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S2213-8587(13)70203-1","article-title":"Endocrine aspects of bone metastases","volume":"2","author":"Hofbauer","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S1470-2045(17)30695-2_bib5","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.ejca.2014.04.002","article-title":"Age at diagnosis and distant metastasis in breast cancer\u2014a surprising inverse relationship","volume":"50","author":"Purushotham","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1470-2045(17)30695-2_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(17)30695-2_bib7","doi-asserted-by":"crossref","first-page":"djv256","DOI":"10.1093\/jnci\/djv256","article-title":"Enhanced MAF oncogene expression and breast cancer bone metastasis","volume":"107","author":"Pavlovic","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S1470-2045(17)30695-2_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30603-4","article-title":"Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01\/04) trial","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(17)30695-2_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(17)30695-2_bib10","doi-asserted-by":"crossref","first-page":"djv360","DOI":"10.1093\/jnci\/djv360","article-title":"CAPG and GIPC1: breast cancer biomarkers for bone metastasis development and treatment","volume":"108","author":"Westbrook","year":"2016","journal-title":"J Natl Cancer Inst"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204517306952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204517306952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:18:49Z","timestamp":1761459529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204517306952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1470204517306952"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(17)30695-2","relation":{},"ISSN":["1470-2045"],"issn-type":[{"type":"print","value":"1470-2045"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant zoledronic acid to treat breast cancer: not for all","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(17)30695-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(17)30603-4","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}